Recent News

• 03.04.2025 - Fourth Quarter and Full Year 2024 Financial Results
• 03.04.2025 - Fourth Quarter and Full Year 2024 Financial Results
• 03.04.2025 - Esperion Reports Fourth Quarter and Full Year 2024 Financial Results
• 03.04.2025 - Esperion Reports Fourth Quarter and Full Year 2024 Financial Results
• 03.04.2025 - Esperion Reports Fourth Quarter and Full Year 2024 Financial Results
• 03.03.2025 - Esperion Partners with CSL Seqirus to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Australia
• 03.03.2025 - Esperion Partners with CSL Seqirus to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Australia
• 03.03.2025 - Esperion Partners with CSL Seqirus to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Australia
• 02.18.2025 - Esperion to Report Fourth Quarter and Full Year 2024 Financial Results on March 4
• 02.18.2025 - Esperion to Report Fourth Quarter and Full Year 2024 Financial Results on March 4

Recent Filings

• 02.20.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.20.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.19.2025 - 144 Report of proposed sale of securities
• 02.19.2025 - 144 Report of proposed sale of securities
• 02.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors